Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy Volunteers

NCT ID: NCT01997879

Last Updated: 2023-08-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-11-30
• Study Completion Date: 2013-11-30

Brief Summary

The purpose of this study is to assess systemic safety and absorption of AR-13324 in healthy volunteers.

Conditions

Healthy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

AR-13324 Ophthalmic Solution, 0.02%

Eyedrop

Group Type: EXPERIMENTAL

AR-13324 Ophthalmic Solution, 0.02%

Intervention Type: DRUG

Eyedrop

Interventions

AR-13324 Ophthalmic Solution, 0.02%

Eyedrop

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy adult male or female subjects at least 18 years of age.
• Within 25% of their ideal weights.
• Medically healthy subjects with clinically insignificant screening results (laboratory profiles, medical histories, ECGs, physical exam) as determined by the Investigator.
• Non-tobacco/nicotine using subjects (minimum of 3 months non-tobacco/nicotine use prior to first dose).
• Subjects with two normal (non-diseased) eyes, defined as nonclinically significant in the opinion of the investigator.
• Intraocular pressure between 14 and 20 mm Hg (inclusive) in each eye at Screening/Qualification.
• Best-corrected visual acuity (BCVA) in each eye of 20/40 or better.
• Willing and able to provide written informed consent prior to any study related procedures and to comply with all study requirements.

Exclusion Criteria

• Chronic or acute ophthalmic disease including glaucoma, macular degeneration, clinically significant cataract (primary or secondary). Previous cataract surgery.
• Known hypersensitivity to any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics.
• Previous glaucoma intraocular surgery or glaucoma laser procedures.
• Refractive surgery (e.g., radial keratotomy, PRK, LASIK, etc.).
• Ocular trauma within the past six months, or ocular surgery or laser treatment within the past three months (e.g., laser treatment for glaucoma or retina).
• Evidence of ocular infection, inflammation, cystoid macular edema, clinically significant blepharitis or conjunctivitis at (Screening/ Qualification), or a history of herpes simplex keratitis.
• Ocular medication of any kind within 30 days of Screening/ Qualification
• Any abnormality preventing reliable applanation tonometry of either eye.
• Central corneal thickness greater than 600 µm.
• Cannot demonstrate proper delivery of the eye drop.
• Blood donations or blood loss, within the past 3 months, that would put the patient at risk with the multiple blood samples required in the present study.
• Clinically significant abnormalities in laboratory tests at screening.
• Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, cardiovascular or endocrine disorders) which might interfere with the study.
• Participation in any investigational study within the past 30 days prior to screening.
• Changes of systemic medication that could have a substantial effect on IOP within 30 days prior to screening, or anticipated during the study.
• Due to status of preclinical safety program, women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a physician-supervised form of birth control for at least the last two months. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative urine or serum pregnancy test result at the screening examination and must not intend to become pregnant during the study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Aerie Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Celerion

Phoenix, Arizona, United States

Countries

United States

Other Identifiers

AR13324-CS101

Identifier Type: -

Identifier Source: org_study_id